Suppr超能文献

酮康唑治疗系统性真菌病:系统性和致病性真菌临床分离株对酮康唑的体外敏感性

Treatment of systemic mycoses with ketoconazole: in vitro susceptibilities of clinical isolates of systemic and pathogenic fungi to ketoconazole.

作者信息

Shadomy S, White S C, Yu H P, Dismukes W E

出版信息

J Infect Dis. 1985 Dec;152(6):1249-56. doi: 10.1093/infdis/152.6.1249.

Abstract

Ketoconazole was tested in vitro in three different media against 69 isolates of pathogenic fungi by using a macro-broth dilution procedure. The dimorphic systemic pathogens were highly susceptible, with most isolates of Blastomyces dermatitidis and Histoplasma capsulatum being inhibited and killed by concentrations less than or equal to 0.39 micrograms of ketoconazole/ml. Most isolates of Coccidioides immitis were also inhibited or killed by 0.39 micrograms of ketoconazole/ml; however, several were not killed by 100 micrograms/ml. Isolates of Cryptococcus neoformans and Sporothrix schenckii appeared to be less susceptible, with many isolates being resistant to less than or equal to 1.56 micrograms of ketoconazole/ml. There were 19 isolates of B. dermatitidis, C. immitis, and H. capsulatum recovered from 12 patients either during or following treatment with ketoconazole. Evidence for selection of secondary resistance to ketoconazole in these isolates was not observed. Results of these in vitro studies correlated poorly with the clinical responses to ketoconazole observed in the patients from whom the isolates were recovered.

摘要

采用常量肉汤稀释法,在三种不同培养基中对69株致病真菌分离株进行了酮康唑的体外测试。双相性系统病原体高度敏感,大多数皮炎芽生菌和荚膜组织胞浆菌分离株在酮康唑浓度小于或等于0.39微克/毫升时即被抑制和杀灭。大多数粗球孢子菌分离株也被0.39微克/毫升的酮康唑抑制或杀灭;然而,有几株在100微克/毫升时未被杀死。新型隐球菌和申克孢子丝菌分离株似乎不太敏感,许多分离株对小于或等于1.56微克/毫升的酮康唑耐药。从12例接受酮康唑治疗期间或之后的患者中分离出19株皮炎芽生菌、粗球孢子菌和荚膜组织胞浆菌。未观察到这些分离株对酮康唑产生继发性耐药的证据。这些体外研究结果与从分离出这些菌株的患者中观察到的酮康唑临床反应相关性较差。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验